Global Perinatal Infections Market Size Study & Forecast, by Infection Type (Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes, Gonorrhoea, Human Immunodeficiency Virus, Others), By Diagnosis (Maternal Test, Neonatal Test, Others), By Treat

Global Perinatal Infections Market Size Study & Forecast, by Infection Type (Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes, Gonorrhoea, Human Immunodeficiency Virus, Others), By Diagnosis (Maternal Test, Neonatal Test, Others), By Treatment (Antibiotics, Antiviral, Antiretroviral, Others), By Route of Administration (Oral, Parenteral, Others), By End-user (Hospitals, Homecare, Specialty Clinics), and Regional Analysis, 2023-2030

Global Perinatal Infections Market is valued at approximately USD XX billion in 2022 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2023-2030. Perinatal infections are infections that occur during pregnancy or shortly after delivery, which can be transmitted from the mother to the fetus or newborn. These infections is generally caused by bacteria, viruses, fungi, or parasites that exhibit a serious impact on both the mother and the infant. Several common perinatal infections include cytomegalovirus infection, enterovirus infection, genital herpes, gonorrhea, human immunodeficiency virus, others. The surging cases of perinatal infections, growing awareness regarding treatment availability, rising number of government initiatives, spurring demand for personalized medicine, rising inclination towards point-of-care testing are the most prominent factors that are propelling the market demand across the globe.

In addition, the rising incidences of Human Immunodeficiency Virus (HIV) are exhibiting a positive influence on market growth across the globe. Pregnant women with HIV require antiretroviral therapy (ART) to reduce the risk of mother-to-child transmission of the virus. Without proper treatment, the risk of transmission is high and leads to perinatal HIV infection, which can have serious health consequences for the newborn. According to HIV.gov, in 2021it was estimated that nearly 38.4 million people worldwide are suffering from HIV, of which 1.7 million were children (<15 years old) and 36.7 million were adults. Also, in 2021, approximately 1.5 million individuals around the globe acquired HIV. Thereby, the growing awareness and initiatives for HIV prevention and treatment, along with the availability of ART is aids in lessening the chances of perinatal HIV infection, which, in turn, accelerates the global market growth. Moreover, the growing demand for retail pharmacies, as well as the increasing technological advancements in diagnostic tests presents various lucrative opportunities over the forecasting years. However, the lack of skilled professionals and high cost involved in treatment are hindering the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Perinatal Infections Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the increasing preference towards point-of-care testing, rising number of government initiatives, and spurring demand for personalized medicine. Whereas, Asia Pacific is expected to grow at the highest CAGR over the forecasting years. The surging cases of perinatal infections, growing awareness regarding treatment availability, increasing demand for retail pharmacies, and rising healthcare spending are significantly propelling the market demand across the region.

Major market players included in this report are:
Merck KGaA (Germany)
Beckman Coulter Inc. (U.S.)
BIOMERIEUX (France)
Bio-Rad Laboratories, Inc (U.S.)
Danaher (U.S.)
Hologic Inc. (U.S.)
Gilead Sciences, Inc. (U.S.)
Emcure Pharmaceuticals Limited. (India)
Cipla Inc. (U.S.)
Johnson & Johnson Private Limited (U.S.)

Recent Developments in the Market:
In October 2021, Gilead Sciences, Inc. unveiled that the Biktarvy (bictegravir 30 mg/emtricitabine 120 mg/tenofovir alafenamide 15 mg tablets) has received U.S. Food and Drug Administration (FDA) approval for a new low-dose tablet dosage form for children and adolescents that are virologically suppressed or new to antiretroviral therapy and weigh between 14 kg and 25 kg. By approving this supplemental New Drug Application (sNDA), Biktarvy's indication has been extended to encompass younger children who are HIV-infected, bridging the gap between paediatric and adult HIV treatment alternatives.

Global Perinatal Infections Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered - Infection Type, Diagnosis, Treatment, Route of Administration, End-user, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa


The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Infection Type:
Cytomegalovirus Infection
Enterovirus Infection
Genital Herpes
Gonorrhoea
Human Immunodeficiency Virus
Others

By Diagnosis:
Maternal Test
Neonatal Test
Others

By Treatment:
Antibiotics
Antiviral
Antiretroviral
Others

By Route of Administration:
Oral
Parenteral
Others

By End-user:
Hospitals
Homecare
Specialty Clinics

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
Merck KGaA (Germany)
Beckman Coulter Inc. (U.S.)
BIOMERIEUX (France)
Bio-Rad Laboratories, Inc (U.S.)
Danaher (U.S.)
Hologic Inc. (U.S.)
Gilead Sciences, Inc. (U.S.)
Emcure Pharmaceuticals Limited. (India)
Cipla Inc. (U.S.)
Johnson & Johnson Private Limited (U.S.)

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.